Women’s contraceptive choice following the use of Implanon NXT: Findings from a study in Durban, South Africa

Ivana Beesham, Jennifer Smit, Shannon L. Bosman, Cecilia Milford, Mala Panday, Mags Beksinska

Abstract

Implanon NXT was introduced in South Africa (SA) in 2014 to expand the contraceptive method mix. While studies have explored patterns of implant use, data on contraceptive choice following implant removal is limited. Here, we describe contraceptive choice among 120 women requesting Implanon NXT removal, between 2017 and 2018, at an urban reproductive health clinic in Durban, SA. Among women who used the implant for three years (n=91), >50% chose to reinsert Implanon NXT. Reasons for choosing to reinsert included satisfaction with the implant, the desire for a long-acting method and having had no side effects. A third of women chose not to reinsert Implanon NXT after three years due to side effects such as problematic bleeding. Most women requesting early removal of the implant switched to male condoms, injectables or oral contraceptives. Contraceptive services should provide women with contraceptive options and allow women to make informed decisions regarding contraceptive choice, in addition to providing support and managing side effects among Implanon NXT users. (Afr J Reprod Health 2021; 25[1]: 41-48).

Full Text:

PDF

References

National Department of Health (NDoH), Statistics South

Africa (Stats SA), South African Medical Research Council (SAMRC), and ICF. 2019. South Africa Demographic and Health Survey 2016. Pretoria, South Africa, and Rockville, Maryland, USA: NDoH, Stats SA, SAMRC, and ICF.

National Department of Health (NDoH), South Africa.

National Contraception and Fertility Planning Policy and Service Delivery Guidelines. 2012. Pretoria, South Africa; Department of Health.

Mullick S, Chersich MF, Pillay Y and Rees H.

Introduction of the contraceptive implant in South Africa: Successes, challenges and the way forward. S Afr Med J. 2017;107(10):812-814.

World Health Organization (WHO) & Human

Reproduction Programme (hrp). WHO statement on Progestogen-only implants. 2015.

Massyn N, Barron P, Day C, Ndlovu N, Padarath A and

editors. District Health Barometer 2018/19. Durban: Health Systems Trust; February 2020.

National Department of Health (NDoH), Statistics South

Africa (Stats SA), South African Medical Research Council (SAMRC), and ICF. 2018. South Africa Demographic and Health Survey 2016 Key Findings. Pretoria, South Africa, and Rockville, Maryland, USA: NDoH, Stats SA, SAMRC, and ICF.

Mrwebi KP, Goon D Ter, Owolabi EO, Adeniyi OV,

Seekoe E and Ajayi AI. Reasons for Discontinuation of Implanon among Users in Buffalo City Metropolitan Municipality, South Africa: A Cross-Sectional Study. J Reprod Heal 2018;22(221):113–9.

Pillay D, Chersich MF, Morroni C, Pleaner M, Adeagbo

OA, Naidoo N, Mullick S and Rees H. User perspectives on Implanon NXT in South Africa: A survey of 12 public-sector facilities. South African Med J. 2017;107(10):815.

Panday M. The Contraceptive Implant in South Africa –

Four years on . The experience of a family planning department in KwaZulu-Natal. Obstetrics and Gynaecology Forum 2018;(3):18–22.

Castle S and Askew I. Contraceptive Discontinuation:

Reasons, Challenges, and Solutions. 2015. Population Council and Family Planning 2020.

Beesham I, Smit J, Beksinska M, Panday M, Makatini V

and Evans S. Reasons for requesting removal of the hormonal implant, Implanon NXT, at an urban reproductive health clinic in KwaZulu-Natal, South Africa. S Afr Med J. 2019;109(10):750–5.

University of Witwatersrand. REDCap® [Internet].

Available from: https://redcap.core.wits.ac.za/redcap/

StataCorp. 2015. Stata Statistical Software: Release 14.

College Station TSL.

Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M,

Cedeño-Benavides T, Olvera-Porcel C and Bueno-Cavanillas A. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. Contraception 2009;80(5):457–62.

Agrawal A and Robinson C. An assessment of the first 3

years’ of Implanon in Luton. Oxford University Press; 2004. 577 p.

Bahamondes L, Brache V, Meirik O, Ali M, Habib N,

Landoulsi S and WHO Study Group on Contraceptive Implants for Women. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527–38.

World Health Organization Department of Reproductive

Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO, 2018.

Jacobstein R and Polis CB. Progestin-only contraception:

Injectables and implants. Best Pract Res Clin Gynaecol. 2014;28:795–806.

Smit JA and Beksinska ME. Hormonal contraceptive

continuation and switching in South Africa: Implications for evaluating the association of injectable hormonal contraceptive use and HIV. J Acquir Immune Defic Syndr. 2013;62(3):363–5.

Chappell CA, Harkoo I, Szydlo DW, Bunge KE, Singh

D, Nakabiito, Kamira B, Piper JM, Balkus JE, Hillier HL and CAT and MTN-020/ASPIRE Study Team. Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study. Contraception 2019;100(3):214–8.

Refbacks

  • There are currently no refbacks.